Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Nichola Roebuck"'
Autor:
Mari Lahelma, Heini Rauhamaa, Riikka-Leena Leskelä, Outi Isomeri, Juhana Idänpään-Heikkilä, Sari Käkelä, Nichola Roebuck, Barbara Mascialino, Sakari Hietanen, Mikko Loukovaara, Annika Auranen
Publikováno v:
Acta Oncologica, Vol 63, Iss 1 (2024)
Background: Despite recent treatment advances in ovarian cancer (OC), more real-world evidence studies investigating patient outcomes are needed. OCRWE-Finland was an observational cohort study investigating OC outcomes in Finland during the pre-PARP
Externí odkaz:
https://doaj.org/article/28fe666c08f9476b8c185588bfaf5da0
Autor:
Mari Lahelma, Heini Rauhamaa, Outi Isomeri, Juhana Idänpään-Heikkilä, Sari Käkelä, Nichola Roebuck, Barbara Mascialino, Sakari Hietanen, Mikko Loukovaara, Annika Auranen
Publikováno v:
Acta Oncologica, Vol 63, Iss 1 (2024)
Background: As the treatment landscape for advanced ovarian cancer (OC) evolves, it is important to understand patient outcomes in real-world clinical practice. OCRWE-Finland was an observational cohort study investigating OC outcomes, including trea
Externí odkaz:
https://doaj.org/article/ead2c7d6078c40b384938eca60b4f9dc
Autor:
Charlie Gourley, Nichola Roebuck, Kiera Heffernan, Robert L Hollis, Zsofia Kiss, Helen Starkie-Camejo
Publikováno v:
Ovarian cancer.
Introduction/Background Niraparib is an oral, highly selective poly(ADP-ribose) polymerase inhibitor (PARPi). The PRIMA/ENGOT-OV26/GOG-3012 trial intention-to-treat population included stage III and IV ovarian cancer (OC) patients post-primary or int
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::39863de781e52f924137e9bb02416bc7
https://doi.org/10.1136/ijgc-2020-esgo.126
https://doi.org/10.1136/ijgc-2020-esgo.126
